We are headquartered in Carmiel, Israel.
Protalix Ltd. was established in 1993.
Our address is 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel and we can be contacted at Tel: 972-4-988-9488; Fax: 972-4-988-9489.
As of December 31, 2013, we had 260 employees, of whom 40 have an M.D. or a Ph.D. in their respective scientific fields.
Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm. Kesselman & Kesselman is located at Trade Tower, 25 Hamered Street, Tel Aviv 68125, Israel, and can be reached at Tel: 972-3-795-4555 Fax: 972-3-795-4556.
Protalix BioTherapeutics' fiscal year end is December 31.
Information regarding Protalix BioTherapeutics may be obtained through its news releases, presentations and other materials all of which may be accessed directly through this site. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements and other filings with the U.S. Securities and Exchange Commission may be accessed directly through this site or through the Securities and Exchange Commission at www.sec.gov.
Protalix BioTherapeutics’ legal team is Morrison & Foerster LLP; they may be reached at 212-468-8000.
Protalix BioTherapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC. The transfer agent may be reached at (800) 937-5449 or (718) 921-8124. Please see www.amstock.com for additional information regarding the transfer agent.
Protalix BioTherapeutics is a dual-listed company. Its common stock trades on the NYSE MKT under the ticker symbol PLX and the CUSIP is 74365A101. Protalix BioTherapeutics’ U.S. ISIN is US74365A1016.
Protalix BioTherapeutics common stock is also listed on the Tel Aviv Stock Exchange and, accordingly, Protalix BioTherapeutics submits copies of its filings with the U.S. Securities and Exchange Commission to the Israeli Securities Authority and the Tel Aviv Stock Exchange. Such copies can be retrieved electronically through the Tel Aviv Stock Exchange’s internet messaging system (www.maya.tase.co.il ) and through the MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).
J. Streicher & Co., LLC
As of November 1, 2014, Protalix BioTherapeutics had approximately 93,672,564 shares of its common stock, par value $0.001 per share, outstanding.
No, Protalix BioTherapeutics does not pay a dividend.
Protalix BioTherapeutics currently discloses financial information in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.
Protalix BioTherapeutics held its last annual meeting of shareholders last November, and generally holds such shareholder meetings during the month of November.
Protalix BioTherapeutics became a U.S. public company through a reverse merger with Orthodontix Inc. on December 31, 2006. On October 25, 2007, Protalix BioTherapeutics issued and sold 10,000,000 shares of common stock in an underwritten public offering at a price of $5.00 per share.